ArticleHematology, transfusion and cell therapy
Evaluation of vaccine-induced antibody responses against SARS-CoV-2 in multiple myeloma patients from the northeastern region of Mexico.
Article in Hematology, transfusion and cell therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate immunoglobulin G antibody responses against Severe Acute Respiratory Syndrome Coronavirus 2 in multiple myeloma patients in the northeastern region of Mexico following different COVID-19 vaccination regimens.
methodsThis retrospective study included 33 multiple myeloma patients, and 28 healthy controls vaccinated with mRNA (BNT162b2, mRNA-1273) or adenovector (AZD1222) vaccines. Anti-spike receptor-binding domain (RBD) and anti-nucleocapsid immunoglobulin G levels were measured. Laboratory parameters, including monocyte and lymphocyte counts and serum-free light chains, were analyzed. Statistical comparisons used ANOVA, Kruskal-Wallis, and logistic regression.
resultsNo significant differences in anti-spike receptor-binding domain immunoglobulin G levels were observed between multiple myeloma patients and healthy controls after one vaccine dose. Multiple myeloma patients who received ≥3 doses showed higher anti-spike receptor-binding domain immunoglobulin G levels compared to single-dose recipients. Anti-nucleocapsid antibodies (indicative of prior subclinical infection) were detected in 51.5% of multiple myeloma patients and correlated with elevated anti-spike receptor-binding domain levels. Patients in the third anti-spike immunoglobulin G quartile (10,427.9-23,954.0 AU/mL) had higher monocyte counts compared with patients in the lower quartiles. No correlations were found between anti-spike immunoglobulin G and lymphocyte counts, serum proteins, or gamma globulins. Abnormal kappa/lambda light chain ratios did not impair antibody responses in nucleocapsid-positive patients.
conclusionMultiple myeloma patients achieved comparable immunoglobulin G responses to healthy controls after one vaccine dose, with enhanced responses following ≥3 doses. Subclinical infections may augment humoral immunity. Elevated monocyte counts are indicative of innate immune activation following the administration of the vaccine. These findings support prioritizing booster doses for multiple myeloma patients despite immunosuppressive therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.